je.st
news
Home
› Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015
Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015
2015-06-01 12:09:35| Logistics - Topix.net
Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology Annual Meeting being held in Chicago from May 29-June 2, 2015. The Company also provided updates on its other targeted tyrosine kinase inhibitor, MGCD516, and spectrum-selective HDAC inhibitor, mocetinostat.
Tags: results
presents
preliminary
inhibitor
Category:Transportation and Logistics
Latest from this category |
All news |
||||||||||||||||||
|
|||||||||||||||||||